Caryn Parlavecchio Sells 6,600 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Caryn Parlavecchio sold 6,600 shares of Scholar Rock stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $44.48, for a total transaction of $293,568.00. Following the completion of the sale, the insider owned 148,864 shares of the company’s stock, valued at $6,621,470.72. This trade represents a 4.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Scholar Rock Stock Up 3.8%

NASDAQ:SRRK opened at $47.82 on Friday. Scholar Rock Holding Corporation has a 52 week low of $22.71 and a 52 week high of $48.28. The stock’s fifty day moving average is $43.59 and its two-hundred day moving average is $37.24. The stock has a market capitalization of $4.88 billion, a price-to-earnings ratio of -15.18 and a beta of 0.63. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the firm posted ($0.66) earnings per share. Research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently modified their holdings of SRRK. Vanguard Group Inc. grew its stake in shares of Scholar Rock by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after purchasing an additional 53,333 shares in the last quarter. Wellington Management Group LLP raised its stake in Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after buying an additional 2,521,022 shares in the last quarter. Bellevue Group AG lifted its holdings in Scholar Rock by 10.1% during the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after buying an additional 297,242 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in Scholar Rock by 9.5% during the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after buying an additional 251,638 shares during the last quarter. Finally, Holocene Advisors LP acquired a new position in shares of Scholar Rock during the 3rd quarter worth about $91,670,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Citigroup started coverage on shares of Scholar Rock in a research note on Friday, January 9th. They issued a “buy” rating and a $55.00 price objective for the company. UBS Group initiated coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Wednesday, October 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $50.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).